Skinvisible Inc (SKVI) Financial Statements (2024 and earlier)

Company Profile

Business Address 6320 S SANDHILL ROAD
LAS VEGAS, NV 89120
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4298112716025
Cash and cash equivalents4298112716025
Receivables5519555
Other undisclosed current assets51399695
Total current assets:607311013817535
Noncurrent Assets
Intangible assets, net (including goodwill)137133137141146148
Intangible assets, net (excluding goodwill)137133137141146148
Total noncurrent assets:137133137141146148
TOTAL ASSETS:196206247279321184
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2281261,2021,1111,025945
Accrued liabilities2,2662,1101,956   
Other undisclosed accounts payable and accrued liabilities(2,037)(1,984)(754)1,1111,025945
Debt      
Due to related parties   27
Other undisclosed current liabilities2,7522,6002,4432,5112,3862,095
Total current liabilities:2,9802,7263,6453,6223,4113,067
Noncurrent Liabilities
Long-term debt and lease obligation5,3725,372    
Long-term debt, excluding current maturities5,3725,372    
Other undisclosed noncurrent liabilities2752633,2422,8972,7322,747
Total noncurrent liabilities:5,6485,6353,2422,8972,7322,747
Total liabilities:8,6288,3626,8876,5196,1435,814
Equity
Equity, attributable to parent(8,432)(8,156)(6,641)(6,240)(5,822)(5,630)
Common stock555555
Additional paid in capital30,35330,35330,35330,35330,35330,353
Accumulated deficit(38,789)(38,513)(36,998)(36,597)(36,179)(35,988)
Total equity:(8,432)(8,156)(6,641)(6,240)(5,822)(5,630)
TOTAL LIABILITIES AND EQUITY:196206247279321184

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues555920560
Cost of revenue    (3) (2)
Gross profit:555620558
Operating expenses(118)(133)(123)(133)(119)(138)
Other operating expense, net
(Other Expenses)
(163)(1,387)(986)   
Other undisclosed operating income1631,387986   
Operating income (loss):(113)(128)(118)(127)86(80)
Interest and debt expense(168)(1,384)(291)(291)(282)(154)
Loss from continuing operations:(280)(1,512)(409)(418)(196)(233)
Loss before gain (loss) on sale of properties:(418)(196)(233)
Net loss:(280)(1,512)(409)(418)(196)(233)
Other undisclosed net income (loss) attributable to parent4(3)80519
Net loss available to common stockholders, diluted:(276)(1,515)(401)(418)(192)(215)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(280)(1,512)(409)(418)(196)(233)
Comprehensive loss, net of tax, attributable to parent:(280)(1,512)(409)(418)(196)(233)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: